NCT03254732 2022-04-27Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid CancersPolaris GroupPhase 1 Terminated33 enrolled
NCT02875093 2020-03-05Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AMLPolaris GroupPhase 1 Terminated23 enrolled